. Author manuscript; available in PMC: 2020 May 15.

Published in final edited form as: Am J Cardiol. 2019 Feb 23;123(10):1660–1666. doi: 10.1016/j.amjcard.2019.02.025

Table 2.

Subgroup Analysis: Change in Metrics of Volitional Physical Activity, Functional Performance, Quality of Life, and Natriuretic Peptides from Baseline after Isosorbide Mononitrate Therapy.

Endpoint
Variable	Change in ADAUs	P interaction	Change in hours active per day	P interaction	Change in 6MWD	P interaction	Change in KCCQ Score	P interaction	Change in NT-proBNP	P interaction
AF/AFL
Yes	−615.5 (−1976.4, −22.0)	0.87	−0.23 (−1.04, 0.47)	0.82	2.8 (−48.0, 28.2)	0.23	−1.0 (−4.8, 4.4)	0.93	−5.5 (−135.0, 133.3)	<0.001
No	−479.1 (−1768.7, 462.5)		−0.20 (−1.02, 0.46)		−8.1 (−41.3, 23.3)		3.5 (−4.6, 15.9)		14.3 (−14.5, 84.7)

Change in endpoints are displayed as median (interquartile range). All models are adjusted for baseline levels of respective endpoints.

6MWD = 6-minute walk distance; ADAUs= Average daily accelerometer units; AF/AFL: atrial fibrillation and/or atrial flutter; KCCQ= Kansas City Cardiomyopathy Questionnaire; NT-proBNP= N-terminal pro-B-type natriuretic peptide.